Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Lymphoma
  Free Subscription

Articles published in
Blood
    May 2024
  1. HILTON LK, Collinge BJ, Ben-Neriah S, Alduaij W, et al
    Motive and Opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements-an LLMPP study.
    Blood. 2024 May 3:blood.2024024251. doi: 10.1182/blood.2024024251.
    >> Share

  2. KIM J, Cho J, Lee MH, Yoon SE, et al
    Comparison of CAR T-cell vs. bispecific antibody as third- or later-line large B-cell lymphoma therapy: A Meta-analysis.
    Blood. 2024 May 2:blood.2023023419. doi: 10.1182/blood.2023023419.
    >> Share

  3. ARORA J, Ayyappan S, Yin C, Smith BJ, et al
    T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC.
    Blood. 2024;143:1816-1824.
    >> Share

    April 2024
  4. SARKOZY C, Callanan MB, Thieblemont C, Oberic L, et al
    Obinutuzumab versus Rituximab in transplant-eligible Mantle cell lymphoma patients.
    Blood. 2024 Apr 26:blood.2024023944. doi: 10.1182/blood.2024023944.
    >> Share

  5. HANDUNNETTI SM, Anderson MA, Burbury KI, Thompson PA, et al
    Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.
    Blood. 2024 Apr 25:blood.2023023388. doi: 10.1182/blood.2023023388.
    >> Share

  6. CROCHET G, Iacoboni G, Couturier A, Bachy E, et al
    Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma.
    Blood. 2024 Apr 24:blood.2024024526. doi: 10.1182/blood.2024024526.
    >> Share

  7. MAYBURY BD, James LJ BSc (Hons), Phillips N, Venkatadasari I, et al
    Testing for t(3;8) in MYC/BCL6 re-arranged large B cell lymphoma identifies a high risk subgroup with inferior survival.
    Blood. 2024 Apr 22:blood.2024024048. doi: 10.1182/blood.2024024048.
    >> Share

  8. LOCKE FL, Siddiqi T, Jacobson CA, Ghobadi A, et al
    Real-World and Clinical Trial Outcomes in Large B-cell Lymphoma with Axicabtagene Ciloleucel Across Race and Ethnicity.
    Blood. 2024 Apr 18:blood.2023023447. doi: 10.1182/blood.2023023447.
    >> Share

  9. SUREDA-GOMEZ M, Iaccarino I, De Bolos A, Meyer MA, et al
    SOX11 expression is restricted to EBV-negative Burkitt lymphoma and associates with molecular genetic features.
    Blood. 2024 Apr 15:blood.2023023242. doi: 10.1182/blood.2023023242.
    >> Share

  10. MERLIO JP
    Staphylococcus aureus and Sezary syndrome.
    Blood. 2024;143:1436-1438.
    >> Share

  11. WEI Q, Bueso-Ramos CE
    Thymoma with aberrant expression of CD20: a potential diagnostic pitfall of B-cell lymphoma.
    Blood. 2024;143:1551.
    >> Share

  12. VADIVEL CK, Willerslev-Olsen A, Namini MRJ, Zeng Z, et al
    Staphylococcus aureus induces drug resistance in cancer T cells in Sezary syndrome.
    Blood. 2024;143:1496-1512.
    >> Share

  13. KROEZE E, Iaccarino I, Kleisman MM, Mondal M, et al
    Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma.
    Blood. 2024 Apr 8:blood.2024023938. doi: 10.1182/blood.2024023938.
    >> Share

  14. MARCAIS A
    Targeting PD-L1 to treat ATLL?
    Blood. 2024;143:1320-1322.
    >> Share

  15. LOCKE FL, Oluwole OO, Kuruvilla J, Thieblemont C, et al
    Axicabtagene ciloleucel versus standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume.
    Blood. 2024 Apr 1:blood.2023021620. doi: 10.1182/blood.2023021620.
    >> Share

    March 2024
  16. GROVER NS, Beaven AW
    T-cell lymphoma: the CAR-T revolution is coming.
    Blood. 2024;143:1201-1202.
    >> Share

  17. GIESSINGER J, Pullarkat ST
    An unusual presentation of lymphoplasmacytic lymphoma with isolated brachial plexus infiltration and amyloidosis.
    Blood. 2024;143:1315.
    >> Share


  18. Zinzani PL, Thieblemont C, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170. Blood. 2023;142(2):141-145.
    Blood. 2024;143:1316.
    >> Share

  19. HILL LC, Rouce RH, Wu MJ, Wang T, et al
    Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas.
    Blood. 2024;143:1231-1241.
    >> Share

  20. STEIDL C, Stevenson FK
    Introduction to a review series on the influence of the tumor microenvironment on the pathogenesis of B-cell lymphomas.
    Blood. 2024;143:1057-1058.
    >> Share

  21. RYAN CE, Armand P, LaCasce AS
    Frontline Treatment of Mantle Cell Lymphoma.
    Blood. 2024 Mar 18:blood.2023022352. doi: 10.1182/blood.2023022352.
    >> Share

  22. GODFREY JK, Gao L, Shouse G, Song JY, et al
    Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma.
    Blood. 2024 Mar 14:blood.2024024168. doi: 10.1182/blood.2024024168.
    >> Share

  23. MOLIN D
    Aging Kairos: treating older Hodgkin patients.
    Blood. 2024;143:943-945.
    >> Share

  24. EL HUSSEIN S
    Monomorphic epitheliotropic T-cell lymphoma with strong CD4 expression.
    Blood. 2024;143:1055.
    >> Share

  25. HAYASHI RJ, Hermiston ML, Wood BL, Teachey DT, et al
    MRD at the End of Induction and EFS in T-cell Lymphoblastic Lymphoma: Children's Oncology Group Trial AALL1231.
    Blood. 2024 Mar 8:blood.2023021184. doi: 10.1182/blood.2023021184.
    >> Share

  26. AHMED R, Feldman AL
    Occult ALK-negative anaplastic large cell lymphoma complicating chronic lymphocytic leukemia.
    Blood. 2024;143:938.
    >> Share

    February 2024
  27. SCHUSTER SJ, Huw LY, Bolen CR, Maximov V, et al
    Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas.
    Blood. 2024;143:822-832.
    >> Share

  28. FRIEDBERG JW, Bordoni R, Patel-Donnelly D, Larson T, et al
    Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy.
    Blood. 2024;143:786-795.
    >> Share

  29. OLSZEWSKI AJ
    When B cells rebuff bispecifics.
    Blood. 2024;143:744-746.
    >> Share

  30. LYNCH RC
    Toward a cure for cHL without chemotherapy.
    Blood. 2024;143:741-742.
    >> Share

  31. ANG Z, Thomas-Tikhonenko A
    Lymphoma immunotherapy: the garden of forking paths.
    Blood. 2024;143:655-657.
    >> Share

  32. SCHOOLCRAFT DK, Karrs JX
    Flower cell morphology in high-grade B-cell lymphoma of the maxillary sinus.
    Blood. 2024;143:738.
    >> Share

  33. BOARDMAN AP, Palomba ML
    Does BTKi improve CAR T-cell therapy in MCL?
    Blood. 2024;143:653-655.
    >> Share

  34. TONINO SH, Kersten MJ
    The quest for a cure in follicular lymphoma.
    Blood. 2024;143:475-476.
    >> Share

  35. WINTER JN, Ferreri AJM
    Predicting outcomes in CNS lymphoma with ctDNA.
    Blood. 2024;143:478-480.
    >> Share

  36. HEGER JM, Mattlener J, Schneider J, Godel P, et al
    Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA.
    Blood. 2024;143:522-534.
    >> Share

  37. CASULO C
    How do you define treatment success in MZL?
    Blood. 2024;143:382-383.
    >> Share

  38. DARNELL EP, Frigault MJ
    Two years later: CD19 CAR-T going the distance.
    Blood. 2024;143:379-380.
    >> Share

  39. GANDHI MK, Kelly GL
    EBNA2: a viral maestra conducting a symphony orchestra.
    Blood. 2024;143:384-385.
    >> Share

    January 2024
  40. MORSY MHA, Lilienthal I, Lord M, Merrien M, et al
    SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma.
    Blood. 2024 Jan 18:blood.2023022241. doi: 10.1182/blood.2023022241.
    >> Share

  41. CERCHIETTI L
    Genetic mechanisms underlying tumor microenvironment composition and function in diffuse large B cell lymphoma.
    Blood. 2024 Jan 11:blood.2023021002. doi: 10.1182/blood.2023021002.
    >> Share

  42. COPPO P, Ricard L
    Plasmablastic lymphoma: better refine prognosis.
    Blood. 2024;143:101-102.
    >> Share

  43. DREYLING M, Fowler NH, Dickinson M, Martinez-Lopez J, et al
    Durable Response After Tisagenlecleucel in Adults With Relapsed/Refractory Follicular Lymphoma: ELARA Trial Update.
    Blood. 2024 Jan 9:blood.2023021567. doi: 10.1182/blood.2023021567.
    >> Share

  44. RADTKE A, Roschewski M
    The follicular lymphoma tumor microenvironment at single cell and spatial resolution.
    Blood. 2024 Jan 9:blood.2023020999. doi: 10.1182/blood.2023020999.
    >> Share

    December 2023
  45. BARRACLOUGH A, Hawkes EA
    Tribulations of trials in aggressive lymphoma.
    Blood. 2023;142:2232-2234.
    >> Share

  46. VEELKEN H
    Energy overpowers sweet tooth in FL.
    Blood. 2023;142:2226-2229.
    >> Share

  47. CHIBA M, Shimono J, Suto K, Ishio T, et al
    Whole genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in Adult T-cell leukemia/lymphoma.
    Blood. 2023 Dec 24:blood.2023021423. doi: 10.1182/blood.2023021423.
    >> Share

  48. SHEA L, Mehta-Shah N
    Peripheral T-cell lymphoma: Are all patients high-risk?
    Blood. 2023 Dec 24:blood.2023020912. doi: 10.1182/blood.2023020912.
    >> Share

  49. FU L, Gong S
    KMT2A-rearranged B-lymphoblastic leukemia/lymphoma with surface light chain restriction and lacking immature markers.
    Blood. 2023;142:2220.
    >> Share

  50. LAURENT C, Dietrich S, Tarte K
    Cell crosstalk within lymphoma tumor microenvironment: follicular lymphoma as a paradigm.
    Blood. 2023 Dec 14:blood.2023021000. doi: 10.1182/blood.2023021000.
    >> Share

  51. SPAARGAREN M
    What's brewing for MALT1 in lymphoma?
    Blood. 2023;142:1939-1941.
    >> Share

  52. LUU BE, Xu SA
    A peculiar case of cyclin D1-positive lymphoplasmacytic lymphoma.
    Blood. 2023;142:2034.
    >> Share

  53. WIMBERGER N, Ober F, Avar G, Grau M, et al
    Oncogene-induced MALT1 protease activity drives posttranscriptional gene expression in malignant lymphomas.
    Blood. 2023;142:1985-2001.
    >> Share

    November 2023
  54. RAUERT-WUNDERLICH H
    EGR1 changes course in B-cell lymphoma.
    Blood. 2023;142:1850-1851.
    >> Share

  55. CAI J, Lee J
    Cold agglutinin syndrome with unexpected bone marrow CD5+ diffuse large B-cell lymphoma.
    Blood. 2023;142:1935.
    >> Share

  56. ALDERUCCIO JP, Nayak L, Cwynarski K
    How I treat secondary CNS involvement by aggressive lymphomas.
    Blood. 2023;142:1771-1783.
    >> Share

  57. STEVENSON FK PROFESSOR, Forconi F
    The essential microenvironmental role of oligomannoses inserted into the antigen-binding sites of lymphoma cells.
    Blood. 2023 Nov 22:blood.2023022703. doi: 10.1182/blood.2023022703.
    >> Share

  58. GHESQUIERES H, Krzisch D, Nicolas Virelizier E, Kanoun S, et al
    Phase 2 LYSA study of prednisone, vinblastine, doxorubicin, bendamustine for untreated older Hodgkin lymphoma patients.
    Blood. 2023 Nov 18:blood.2023021564. doi: 10.1182/blood.2023021564.
    >> Share

  59. DUELL J, Leipold AM, Appenzeller S, Fuhr V, et al
    Sequential Antigen-loss and Branching Evolution in Lymphoma after CD19- and CD20-Targeted T-cell Redirecting Therapy.
    Blood. 2023 Nov 17:blood.2023021672. doi: 10.1182/blood.2023021672.
    >> Share

  60. MURAKAMI MA
    Toward rational therapy for mantle cell lymphoma.
    Blood. 2023;142:1504-1506.
    >> Share

  61. ETANCELIN P, Boussaid I
    Two sides of the same coin: transdifferentiation from Burkitt lymphoma to histiocytic sarcoma.
    Blood. 2023;142:1576.
    >> Share

    October 2023
  62. ABRAMSON JS, Palomba ML, Gordon LI, Lunning MA, et al
    Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001.
    Blood. 2023 Oct 27:blood.2023020854. doi: 10.1182/blood.2023020854.
    >> Share

  63. MINSON AG, Hamad N, Cheah CY, Tam CS, et al
    CAR T-cells and Time-Limited Ibrutinib as Treatment for Relapsed/Refractory Mantle Cell Lymphoma: Phase II TARMAC Study.
    Blood. 2023 Oct 26:blood.2023021306. doi: 10.1182/blood.2023021306.
    >> Share

  64. BROCKELMANN PJ
    AXL-erating mantle cell lymphoma treatment.
    Blood. 2023;142:1411-1412.
    >> Share

  65. GINI G, Tani M, Tucci A, Marcheselli L, et al
    Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study.
    Blood. 2023;142:1438-1447.
    >> Share

  66. NEELAPU SS, Chavez JC, Sehgal A, Epperla N, et al
    Three-Year Follow-Up Analysis of Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5).
    Blood. 2023 Oct 25:blood.2023021243. doi: 10.1182/blood.2023021243.
    >> Share

  67. COLLINS GP
    Tackling PD1i resistance in Hodgkin lymphoma.
    Blood. 2023;142:1333-1334.
    >> Share

  68. BELADA D, Kopeckova K, Bergua Burgues JM, Stevens D, et al
    Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.
    Blood. 2023;142:1348-1358.
    >> Share

  69. LEOPIZZI M, Mundo L, Messina E, Campolo F, et al
    Epstein-Barr virus encoded EBNA2 downregulates ICOSL by inducing miR-24 in B-cell lymphoma.
    Blood. 2023 Oct 17:blood.2023021346. doi: 10.1182/blood.2023021346.
    >> Share

  70. DI CIACCIO PR, Polizzotto MN, Cwynarski K, Gerrie AS, et al
    The Influence of Immunodeficiency, Disease Features and Patient Characteristics on Survival in Plasmablastic Lymphoma.
    Blood. 2023 Oct 13:blood.2023021348. doi: 10.1182/blood.2023021348.
    >> Share

  71. BOMMIER C, Zucca E, Chevret S, Conconi A, et al
    Early Complete Response as Validated Surrogate Marker in Extranodal Marginal Zone Lymphoma Systemic Therapy.
    Blood. 2023 Oct 6:blood.2023020984. doi: 10.1182/blood.2023020984.
    >> Share

  72. RUSSLER-GERMAIN DA, Cliff ERS, Bartlett NL
    Cell-of-Origin Effect of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma: No Ordinary Subgroup Analysis.
    Blood. 2023 Oct 5:blood.2023022048. doi: 10.1182/blood.2023022048.
    >> Share


  73. Jain MD, Ziccheddu B, Coughlin CA, et al. Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. Blood. 2022;140(5):491-503.
    Blood. 2023;142:1255.
    >> Share

  74. MANDATO E, Yan Q, Ouyang J, Paczkowska J, et al
    MYD88L265P augments proximal B-cell receptor signaling in large B-cell lymphomas via an interaction with DOCK8.
    Blood. 2023;142:1219-1232.
    >> Share

    September 2023

  75. Balsas P, Veloza L, Clot G, et al. SOX11, CD70, and Treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma. Blood. 2021;138(22):2202-2215.
    Blood. 2023;142:1173-1176.
    >> Share

  76. NARITA K, Takeuchi K
    FISH for EBV genome in a patient with diffuse large B-cell lymphoma harboring t(14;18)(q32;q21).
    Blood. 2023;142:1172.
    >> Share

  77. ZHOU N, Busino L
    Targeting epigenetics and ferroptosis in DLBCL.
    Blood. 2023;142:1108-1109.
    >> Share

  78. DIEPSTRA A, Nolte IM, van den Berg A, Magpantay LI, et al
    Elevated serum TARC levels precede classic Hodgkin lymphoma diagnosis by several years.
    Blood. 2023 Sep 25:blood.2023020959. doi: 10.1182/blood.2023020959.
    >> Share

  79. LIU Y, Kimpara S, Hoang NM, Daenthanasanmak A, et al
    EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B cell lymphoma.
    Blood. 2023 Sep 22:blood.2023020142. doi: 10.1182/blood.2023020142.
    >> Share

  80. QUALLS DA, Lambert N, Caimi PF, Merrill MH, et al
    Tafasitamab and lenalidomide in large B cell lymphoma: real-world outcomes in a multicenter retrospective study.
    Blood. 2023 Sep 22:blood.2023021274. doi: 10.1182/blood.2023021274.
    >> Share

  81. FREEMAN CL, Locke FL
    CARs put age in the rearview mirror.
    Blood. 2023;142:1029-1031.
    >> Share


  82. Williams AM, Salehabadi SM, Xing M, et al. Modifiable risk factors for neurocognitive and psychosocial problems after Hodgkin lymphoma. Blood. 2022;139(20):3073-3086.
    Blood. 2023;142:1028.
    >> Share

  83. ZHOU N, Choi J, Grothusen G, Kim BJ, et al
    DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance.
    Blood. 2023;142:973-988.
    >> Share

  84. HAEBE SE, Day G, Czerwinski DK, Sathe A, et al
    Follicular lymphoma evolves with a surmountable dependency on acquired glycosylation motifs in the B cell receptor.
    Blood. 2023 Sep 8:blood.2023020360. doi: 10.1182/blood.2023020360.
    >> Share

  85. CHEAH CY
    Pembrolizumab: a key for some, but not all, HL.
    Blood. 2023;142:861-862.
    >> Share


  86. Panea RI, Love CL, Shingleton JR, et al. The whole-genome landscape of Burkitt lymphoma subtypes. Blood. 2019;134(19):1598-1607.
    Blood. 2023;142:940.
    >> Share

    August 2023
  87. ALLEN PB
    DMF in CTCL: where do we go from here?
    Blood. 2023;142:753-754.
    >> Share

  88. CALIP GS, Royce TJ
    External validity of lymphoma clinical trials.
    Blood. 2023;142:757-759.
    >> Share

  89. CASEY M, Odhiambo L, Aggarwal N, Shoukier M, et al
    Representation of the population in need for pivotal clinical trials in lymphomas.
    Blood. 2023;142:846-855.
    >> Share

  90. MARCHI E
    PTCL and ICIs: a matter of time and subtype.
    Blood. 2023;142:613-614.
    >> Share

  91. SAKSENA A, Rajgariah A
    A novel case of peripheral T-cell lymphoma, not otherwise specified, with rhabdoid morphology and INI1 loss.
    Blood. 2023;142:675.
    >> Share

  92. DECOMBIS S, Bellanger C, Le Bris Y, Madiot C, et al
    CARD11 gain of function upregulates BCL2A1 and promotes resistance to targeted therapies combination in B-cell lymphoma.
    Blood. 2023 Aug 10:blood.2023020211. doi: 10.1182/blood.2023020211.
    >> Share

  93. PHELAN JD, Jaffe ES
    An AID to follicular lymphoma transformation.
    Blood. 2023;142:500-502.
    >> Share

  94. DING Y, Jaffe ES
    Follicular lymphoma involving the synovium in rheumatoid arthritis.
    Blood. 2023;142:611.
    >> Share

  95. EICHENAUER DA, Buhnen I, Baues C, Kobe C, et al
    Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies.
    Blood. 2023;142:553-560.
    >> Share

  96. EL-MALLAWANY NK, Kamdar KY
    Evolving beyond morphology in pediatric PTLD.
    Blood. 2023;142:400-402.
    >> Share

  97. SYMES E, Venkataraman G
    Peripheral T-cell lymphoma with TFH phenotype and associated indolent T-lymphoblastic proliferation.
    Blood. 2023;142:493.
    >> Share


  98. Gaudio E, Paduano F, Ngankeu A, et al. Heat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas. Blood. 2013;121(2):351-359.
    Blood. 2023;142:495.
    >> Share

  99. SALMERON-VILLALOBOS J, Castrejon-de-Anta N, Guerra-Garcia P, Ramis-Zaldivar JE, et al
    Decoding the molecular heterogeneity of pediatric monomorphic post-solid organ transplant lymphoproliferative disorders.
    Blood. 2023;142:434-445.
    >> Share

    July 2023
  100. GIULINO-ROTH L
    Pembrolizumab in PMBCL: can it go the distance?
    Blood. 2023;142:121-122.
    >> Share

  101. BOYER DF, Perry A, Wey E, Hsueh J, et al
    Fibrin-associated large B-cell lymphoma shows frequent mutations related to immune surveillance and PTEN.
    Blood. 2023 Jul 11:blood.2023020349. doi: 10.1182/blood.2023020349.
    >> Share

  102. TORABI A, Naresh KN
    T-cell prolymphocytic leukemia/lymphoma with TCRB::TCL1 translocation.
    Blood. 2023;142:119.
    >> Share

  103. PARRY EM, Ten Hacken E, Wu CJ
    Richter syndrome: novel insights into the biology of transformation.
    Blood. 2023;142:11-22.
    >> Share

    June 2023
  104. DE VRIES S, Krul I, Schaapveld M, Janus CMP, et al
    Risk of male breast cancer after Hodgkin lymphoma.
    Blood. 2023 Jun 30:blood.2023020940. doi: 10.1182/blood.2023020940.
    >> Share

  105. THOMPSON PA, Tam CS
    Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders.
    Blood. 2023;141:3137-3142.
    >> Share

  106. SELLI ME, Landmann JH, Terekhova M, Lattin J, et al
    Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction.
    Blood. 2023;141:3153-3165.
    >> Share

  107. CHESON BD
    A man's best friend is his PET.
    Blood. 2023;141:3010-3012.
    >> Share

  108. MEI MG, Chen L, Godfrey J, Song JY, et al
    Pembrolizumab plus vorinostat is highly active in Hodgkin lymphoma, including patients refractory to prior PD-1 blockade.
    Blood. 2023 Jun 20:blood.2023020485. doi: 10.1182/blood.2023020485.
    >> Share

  109. CHIHARA D, Liao L, Tkacz J, Franco A, et al
    Real-World Evidence of CAR T-cell Therapy in Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
    Blood. 2023 Jun 20:blood.2023020197. doi: 10.1182/blood.2023020197.
    >> Share

  110. GELEBART P, Gjerstad ME, Benjaminsen S, Han J, et al
    Inhibition of a new AXL isoform (AXL3) induces apoptosis of mantle cell lymphoma cells.
    Blood. 2023 Jun 20:blood.2022015581. doi: 10.1182/blood.2022015581.
    >> Share

  111. SONG Z, Wu W, Wei W, Xiao W, et al
    Analysis and Therapeutic Targeting of the IL-1R Pathway in Anaplastic Large Cell Lymphoma.
    Blood. 2023 Jun 20:blood.2022019166. doi: 10.1182/blood.2022019166.
    >> Share

  112. ARMAND P, Zinzani PL, Lee HJ, Johnson NA, et al
    Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy in relapsed/refractory classical Hodgkin lymphoma.
    Blood. 2023 Jun 15:blood.2022019386. doi: 10.1182/blood.2022019386.
    >> Share

  113. MERRILL MH, Dahi PB, Redd RA, McDonough M, et al
    A Phase 2 Study of pembrolizumab after Autologous Stem Cell Transplantation in Patients with T-Cell non-Hodgkin Lymphoma.
    Blood. 2023 Jun 15:blood.2023020244. doi: 10.1182/blood.2023020244.
    >> Share

  114. YOSIFOV DY, Stilgenbauer S
    Richter transformation: epigenetics to blame?
    Blood. 2023;141:2915-2917.
    >> Share

  115. TSAGIOPOULOU M, Chapaprieta V, Russinol N, Garcia-Torre B, et al
    Chromatin activation profiling of stereotyped chronic lymphocytic leukemias reveals a subset 8-specific signature.
    Blood. 2023;141:2955-2960.
    >> Share

  116. SCHMITT A, Grimm M, Kreienkamp N, Junge H, et al
    BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis.
    Blood. 2023 Jun 9:blood.2022019274. doi: 10.1182/blood.2022019274.
    >> Share

  117. KU A, Alobeid B
    IRF4/DUSP22-positive anaplastic large cell lymphoma arising in the setting of chronic olecranon bursitis.
    Blood. 2023;141:2912.
    >> Share

  118. SLOAN SL, Brown F, Long ME, Weigel C, et al
    PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma.
    Blood. 2023 Jun 2:blood.2022019419. doi: 10.1182/blood.2022019419.
    >> Share

  119. KURUVILLA J
    Targeted therapy in mediastinal gray zone lymphoma.
    Blood. 2023;141:2673-2674.
    >> Share

  120. MERRYMAN RW, LaCasce AS
    Improved survival in cHL with novel agents.
    Blood. 2023;141:2666-2668.
    >> Share

    May 2023
  121. MEI M, Herrera AF
    The next frontier: enter PD-1 and exit PET scans?
    Blood. 2023;141:2545-2546.
    >> Share

  122. SACCO A, Desantis V, Celay J, Giustini V, et al
    Targeting the immune microenvironment in Waldenstrom macroglobulinemia via halting the CD40/CD40-ligand axis.
    Blood. 2023;141:2615-2628.
    >> Share

  123. LUGTENBURG PJ, Mutsaers PGNJ
    How I treat older patients with DLBCL in the frontline setting.
    Blood. 2023;141:2566-2575.
    >> Share

  124. NICOLAY JP, Melchers S, Albrecht JD, Assaf C, et al
    Dimethyl fumarate treatment in relapsed and refractory cutaneous T cell lymphoma - a multicenter phase II study.
    Blood. 2023 May 22:blood.2022018669. doi: 10.1182/blood.2022018669.
    >> Share

  125. ABRAMSON JS
    A new CAR takes a test drive in DLBCL.
    Blood. 2023;141:2410-2411.
    >> Share

  126. YLSTRA B, de Jong D
    DNA or RNA? Classification of B-cell lymphomas.
    Blood. 2023;141:2413-2415.
    >> Share

  127. BALKE-WANT H
    Putting the pedal to the metal: axi-cel for LBCL.
    Blood. 2023;141:2285-2286.
    >> Share

  128. CHABAY P
    Increasing microenvironment complexity in HL.
    Blood. 2023;141:2290-2291.
    >> Share

  129. BIGENWALD C, Zitvogel L
    Light shed from the gut in large B-cell lymphoma.
    Blood. 2023;141:2165-2166.
    >> Share

  130. BARTA SK
    Is it prime time for T-cell lymphoma?
    Blood. 2023;141:2161-2163.
    >> Share

  131. ZINZANI PLL, Thieblemont C, Melnichenko V, Bouabdallah K, et al
    Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170.
    Blood. 2023 May 2:blood.2022019340. doi: 10.1182/blood.2022019340.
    >> Share

    April 2023
  132. JAYE DL, Feldman AL
    ALK-negative anaplastic large cell lymphoma with JAK2 rearrangement mimicking classic Hodgkin lymphoma.
    Blood. 2023;141:2160.
    >> Share

  133. TOLU SS, Amengual JE
    Queen's gambit: response-adapted win in CAYA with cHL.
    Blood. 2023;141:2037-2038.
    >> Share

  134. DREVAL K, Hilton LK, Cruz M, Shaalan H, et al
    Genetic Subdivisions of Follicular Lymphoma Defined by Distinct Coding and non-coding Mutation Patterns.
    Blood. 2023 Apr 21:blood.2022018719. doi: 10.1182/blood.2022018719.
    >> Share

  135. ATTIEH M, Asakrah S
    Indolent NK-cell lymphoproliferative disorder of the GI tract: a rare indolent neoplasm of the GI tract.
    Blood. 2023;141:2033.
    >> Share

  136. SONG Y, Tilly H, Rai S, Zhang H, et al
    Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial.
    Blood. 2023;141:1971-1981.
    >> Share


  137. Tong C, Zhang Y, Liu Y, et al. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. Blood. 2020;136(14):1632-1644.
    Blood. 2023;141:1896.
    >> Share

  138. ATTIEH M, Asakrah S
    B-ALL with synchronous MYC and BCL-2 rearrangement.
    Blood. 2023;141:1894.
    >> Share

  139. BRANDSTOETTER T, Schmoellerl J, Grausenburger R, Kollmann S, et al
    SBNO2 is a critical mediator of STAT3-driven hematological malignancies.
    Blood. 2023;141:1831-1845.
    >> Share

  140. SI LIM S, Ford JB, Hermiston ML
    How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults.
    Blood. 2023 Apr 5:blood.2022016503. doi: 10.1182/blood.2022016503.
    >> Share

    March 2023
  141. EERTINK JJ, Zwezerijnen GJ, Heymans M, Pieplenbosch S, et al
    Baseline PET radiomics outperform the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma.
    Blood. 2023 Mar 31:blood.2022018558. doi: 10.1182/blood.2022018558.
    >> Share


  142. Bonfiglio F, Bruscaggin A, Guidetti F, et al. Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood. 2022;139(5):732-747.
    Blood. 2023;141:1647.
    >> Share


  143. Johnston RL, Mottok A, Chan FC, et al. A gene expression-based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma. Blood. 2022;139(6):889-893.
    Blood. 2023;141:1495.
    >> Share

  144. ROZENOVA KA, Xiao W
    Primary thymic marginal zone lymphoma with amyloidosis.
    Blood. 2023;141:1494.
    >> Share

  145. STACHELSCHEID J, Jiang Q, Aszyk C, Warner K, et al
    The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL.
    Blood. 2023;141:1425-1441.
    >> Share

  146. FOX LC
    Unraveling family ties in Hodgkin lymphoma.
    Blood. 2023;141:1240-1241.
    >> Share

  147. BAYKARA Y, Kurt H
    Low-grade follicular lymphoma with extensive marginal zone differentiation and expression of MUM1 and CD30.
    Blood. 2023;141:1363.
    >> Share

  148. LYNCH RC, Ujjani CS, Poh C, Warren EH, et al
    Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma.
    Blood. 2023 Mar 13:blood.2022019254. doi: 10.1182/blood.2022019254.
    >> Share

  149. CARBONE A, Gloghini A, Carlo Stella C
    Tumor microenvironment contribution to checkpoint blockade therapy. Lessons learned from Hodgkin lymphoma.
    Blood. 2023 Mar 10:blood.2022016590. doi: 10.1182/blood.2022016590.
    >> Share

  150. SANTORO A, Moskowitz AJ, Ferrari S, Carlo-Stella C, et al
    Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma.
    Blood. 2023 Mar 10:blood.2022017951. doi: 10.1182/blood.2022017951.
    >> Share

  151. CHIHARA D
    Synthetic lethality in ATL.
    Blood. 2023;141:1096-1098.
    >> Share

  152. LEFEBVRE C, Szymanski G
    Extranodal presentation of a MYC/BCL6 double-hit lymphoma with 11q aberration in an older patient.
    Blood. 2023;141:1093.
    >> Share

  153. SPINNER MA, Sica RA, Tamaresis JS, Lu Y, et al
    Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents.
    Blood. 2023 Mar 1:blood.2022018827. doi: 10.1182/blood.2022018827.
    >> Share

    February 2023
  154. NEELAPU SS, Jacobson CA, Ghobadi A, Miklos DB, et al
    5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1).
    Blood. 2023 Feb 23:blood.2022018893. doi: 10.1182/blood.2022018893.
    >> Share

  155. RODDIE C, Lekakis LJ, Marzolini MAV, Ramakrishnan A, et al
    Dual targeting of CD19 and CD22 with Bicistronic CAR-T cells in Patients with Relapsed/Refractory Large B Cell Lymphoma.
    Blood. 2023 Feb 23:blood.2022018598. doi: 10.1182/blood.2022018598.
    >> Share

  156. OLSZEWSKI AJ
    Meet the Burkitts: a dark zone family.
    Blood. 2023;141:816-818.
    >> Share

  157. BANGHAM CRM
    HTLV-1 persistence and the oncogenesis of adult T cell leukemia/lymphoma.
    Blood. 2023 Feb 17:blood.2022019332. doi: 10.1182/blood.2022019332.
    >> Share

  158. RUAN J, Moskowitz AJ, Mehta-Shah N, Sokol L, et al
    Multicenter Phase 2 Study of Oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma.
    Blood. 2023 Feb 16:blood.2022018254. doi: 10.1182/blood.2022018254.
    >> Share

  159. CAIRO MS
    EBV: the virus that keeps on giving!
    Blood. 2023;141:689-691.
    >> Share

  160. KHODADOUST MS, Mou E, Kim YH
    Integrating novel agents into the treatment of advanced mycosis fungoides and Sezary syndrome.
    Blood. 2023;141:695-703.
    >> Share

  161. ELITZUR S, Vora A, Burkhardt B, Inaba H, et al
    EBV-driven lymphoid neoplasms associated with pediatric ALL maintenance therapy.
    Blood. 2023;141:743-755.
    >> Share


  162. Westin J, Sehn LH. CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift? Blood. 2022;139(18):2737-2746.
    Blood. 2023;141:683.
    >> Share

  163. STEWART BJ, Fergie M, Young M, Jones C, et al
    Spatial and molecular profiling of the mononuclear phagocyte network in Classic Hodgkin lymphoma.
    Blood. 2023 Feb 7:blood.2022015575. doi: 10.1182/blood.2022015575.
    >> Share

  164. ALDERUCCIO JP, Reis IM, Koff JL, Larson MC, et al
    Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma.
    Blood. 2023 Feb 3:blood.2022019294. doi: 10.1182/blood.2022019294.
    >> Share

  165. PINA-OVIEDO S, Motwani P
    Composite ALK-negative anaplastic large-cell lymphoma and mantle cell lymphoma.
    Blood. 2023;141:556.
    >> Share

  166. KHODADOUST M, Silva O
    Hepatosplenic T-cell lymphoma with STAT5B and SETD2 mutations recurring as cells with NK-cell immunophenotype.
    Blood. 2023;141:555.
    >> Share

  167. YOON SE, Kang W, Choi S, Park Y, et al
    The influence of microbial dysbiosis on immunochemotherapy-related efficacy and safety in diffuse large B-cell lymphoma.
    Blood. 2023 Feb 1:blood.2022018831. doi: 10.1182/blood.2022018831.
    >> Share

    January 2023

  168. Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140(11):1229-1253.
    Blood. 2023;141:437.
    >> Share

  169. JAEGER A, Gambheer SMM, Sun X, Chernyakov D, et al
    Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms.
    Blood. 2023 Jan 25:blood.2022015653. doi: 10.1182/blood.2022015653.
    >> Share

  170. YUAN CT, Chuang SS
    Effusion presentation of HHV-8-associated multicentric Castleman disease mimicking primary effusion lymphoma.
    Blood. 2023;141:320.
    >> Share

  171. NAHMOD KA, Vega F
    ALK-positive large B-cell lymphoma, a rare B-cell lymphoma expressing ALK.
    Blood. 2023;141:209.
    >> Share

  172. SCHLAPBACH C
    TOXic T-cell cytokines wreak havoc in CTCL skin.
    Blood. 2023;141:127-128.
    >> Share

  173. WHITTAKER S, Jones CL
    CD39-CD73-adenosine effects in Sezary syndrome.
    Blood. 2023;141:9-10.
    >> Share

  174. YAKYMIV Y, Marchisio S, Ortolan E, Bracci C, et al
    CD39/CD73 dysregulation and adenosine metabolism contribute to T-cell immunosuppression in patients with Sezary syndrome.
    Blood. 2023;141:111-116.
    >> Share

    December 2022
  175. QIU L, Quesada AE
    Lymphoplasmacytic lymphoma with IgG paraprotein and extensive plasmacytic differentiation mimicking plasma cell neoplasm.
    Blood. 2022;140:2857.
    >> Share

  176. HORNA P, Otteson G, Shi M, Seheult JN, et al
    Improved semiautomated detection of TRBC-restricted Sezary cells unveils a spectrum of clonal cluster immunophenotypes.
    Blood. 2022;140:2852-2856.
    >> Share

  177. HARKER-MURRAY P, Mauz-Korholz C, Leblanc TM, Mascarin M, et al
    Nivolumab, Brentuximab Vedotin, +/- Bendamustine For R/R Hodgkin Lymphoma in Children, Adolescents, and Young Adults.
    Blood. 2022 Dec 23:blood.2022017118. doi: 10.1182/blood.2022017118.
    >> Share

  178. AOKI T, Steidl C
    Novel insights into Hodgkin lymphoma biology by single cell analysis.
    Blood. 2022 Dec 22:blood.2022017147. doi: 10.1182/blood.2022017147.
    >> Share

  179. KIM DH, Thakral B
    False CD10 positivity in MALT lymphoma involving kidney.
    Blood. 2022;140:2760.
    >> Share

  180. SCHEFFER CLIFF ER, Pandya A
    Pola-R-CHP for DLBCL: cost-effective at first glance.
    Blood. 2022;140:2654-2655.
    >> Share

  181. ABRAMSON JS, Solomon SR, Arnason JE, Johnston PB, et al
    Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study.
    Blood. 2022 Dec 21:blood.2022018730. doi: 10.1182/blood.2022018730.
    >> Share

  182. JAFFE ES, Cook JR
    Core biopsy for lymphoma diagnosis? A needling prospect.
    Blood. 2022;140:2525-2527.
    >> Share

  183. FALINI B, Lazzi S
    Pediatric large B-cell lymphoma with 11q aberration.
    Blood. 2022;140:2644.
    >> Share

  184. FALINI B, Lazzi S
    Diffuse large B-cell lymphoma of the testis.
    Blood. 2022;140:2645.
    >> Share

  185. ABRAMSON JS
    Post-CAR relapse in DLBCL: a fork in the road.
    Blood. 2022;140:2527-2529.
    >> Share


  186. Lulla PD. CAR T cells and autologous transplantation can coexist for DLBCL. Blood. 2021;139(9):1266-1267.
    Blood. 2022;140:2646.
    >> Share

  187. DREVAL K, Boutros PC, Morin RD
    Minimal information for reporting a genomics experiment.
    Blood. 2022;140:2549-2555.
    >> Share

  188. KUUSANMAKI H, Dufva O, Vaha-Koskela M, Leppa AM, et al
    Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia.
    Blood. 2022 Dec 12:blood.2021011094. doi: 10.1182/blood.2021011094.
    >> Share

  189. FARINHA P
    A N(ew) MYC joins T-cell lymphomagenesis.
    Blood. 2022;140:2416-2417.
    >> Share

  190. RAHNAMA R, Bonifant CL
    Engineering builds multipotency for iPSC-NKs.
    Blood. 2022;140:2414-2416.
    >> Share

  191. MARTINES C, Chakraborty S, Vujovikj M, Gobessi S, et al
    Macrophage- and BCR-derived but not TLR-derived signals support the growth of CLL and Richter syndrome murine models in vivo.
    Blood. 2022;140:2335-2347.
    >> Share

    November 2022
  192. GHOSH N
    Axi-cel in LBCL: fulfill two needs with one deed.
    Blood. 2022;140:2183-2185.
    >> Share

  193. DE LEVAL L, Alizadeh AA, Bergsagel PL, Campo E, et al
    Genomic profiling for clinical decision making in lymphoid neoplasms.
    Blood. 2022;140:2193-2227.
    >> Share

  194. WILKENS AB, Fulton EC, Pont MJ, Cole GO, et al
    NOTCH1 signaling during CD4+ T-cell activation alters transcription factor networks and enhances antigen responsiveness.
    Blood. 2022;140:2261-2275.
    >> Share

  195. THOMALLA D, Beckmann L, Grimm C, Oliverio M, et al
    Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies.
    Blood. 2022;140:2113-2126.
    >> Share

  196. DELAGE L, Lambert M, Bardel E, Kundlacz C, et al
    BTG1 inactivation drives lymphomagenesis and promotes lymphoma dissemination through activation of BCAR1.
    Blood. 2022 Nov 14. pii: 487109. doi: 10.1182/blood.2022016943.
    >> Share

  197. AMENGUAL JE
    A Tet-a-Tet in T follicular helper cell lymphoma.
    Blood. 2022;140:1919-1921.
    >> Share

  198. CHIBA M, Shimono J, Ishio T, Takei N, et al
    Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas.
    Blood. 2022;140:1951-1963.
    >> Share

  199. FALCHI L, Vardhana SA, Salles GA
    Bispecific antibodies for the treatment of B-cell lymphoma: Promises, unknowns and opportunities.
    Blood. 2022 Nov 2. pii: 486966. doi: 10.1182/blood.2021011994.
    >> Share

    October 2022
  200. RUSHTON CK, Dreval K, Morin RD
    Concerning data inconsistencies in Burkitt lymphoma genome study.
    Blood. 2022 Oct 27. pii: 486935. doi: 10.1182/blood.2022016505.
    >> Share

  201. ALDUAIJ W, Collinge BJ, Ben-Neriah S, Jiang A, et al
    Molecular Determinants of Clinical Outcomes In a Real-World Diffuse Large B-cell Lymphoma Population.
    Blood. 2022 Oct 27. pii: 486923. doi: 10.1182/blood.2022018248.
    >> Share

  202. DAVE SS
    Burkitt lymphoma genomic discovery studies, drivers and validation.
    Blood. 2022 Oct 27. pii: 486922. doi: 10.1182/blood.2022018865.
    >> Share

  203. RUAN J
    Claiming the mantle of the brain.
    Blood. 2022;140:1835-1836.
    >> Share

  204. SHARMA M, Fu MP, Lu HY, Sharma AA, et al
    Human complete NFAT1 deficiency causes a triad of joint contractures, osteochondromas, and B-cell malignancy.
    Blood. 2022;140:1858-1874.
    >> Share

  205. FRONTZEK F, Lenz G
    Tackling ALK-positive LBCL.
    Blood. 2022;140:1751-1752.
    >> Share

  206. ZHAO L, Li S, Wei X, Qi X, et al
    A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL.
    Blood. 2022;140:1790-1802.
    >> Share

  207. THOMAS N, Dreval K, Gerhard DS, Hilton LK, et al
    GENETIC SUBGROUPS INFORM ON PATHOBIOLOGY IN ADULT AND PEDIATRIC BURKITT LYMPHOMA.
    Blood. 2022 Oct 6. pii: 486739. doi: 10.1182/blood.2022016534.
    >> Share

    September 2022
  208. IZUTSU K, Makita S, Nosaka K, Yoshimitsu M, et al
    An Open-Label, Single-Arm, Phase 2 Trial of Valemetostat in Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma.
    Blood. 2022 Sep 23. pii: 486703. doi: 10.1182/blood.2022016862.
    >> Share

  209. BLOMBERY P, Cheah CY
    Predicting the future in MCL with MRD.
    Blood. 2022;140:1332-1333.
    >> Share

  210. GLUUD M, Pallesen EMH, Buus TB, Gjerdrum LMR, et al
    Malignant T cells induce skin barrier defects through cytokine-mediated JAK/STAT signalling in cutaneous T-cell lymphoma.
    Blood. 2022 Sep 19. pii: 486665. doi: 10.1182/blood.2022016690.
    >> Share

  211. DI BLASI R, Le Gouill S, Bachy E, Cartron G, et al
    Outcomes of patients with aggressive B-Cell lymphoma after failure of anti-CD19 CAR T-Cell Therapy: A DESCAR-T analysis.
    Blood. 2022 Sep 19. pii: 486662. doi: 10.1182/blood.2022016945.
    >> Share

  212. CAMPO E, Jaffe ES, Cook JR, Quintanilla-Martinez L, et al
    The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.
    Blood. 2022;140:1229-1253.
    >> Share

  213. HEREK TA, Bouska A, Lone W, Sharma S, et al
    DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOS.
    Blood. 2022;140:1278-1290.
    >> Share

  214. HEGAZY SE, Bailey NG
    Progression of CCND1- in situ mantle cell neoplasia to CCND1- mantle cell lymphoma.
    Blood. 2022;140:1182.
    >> Share

  215. FLERLAGE JE
    Radiotherapy is here to stay.
    Blood. 2022;140:1053-1054.
    >> Share

  216. WEN R, Wang D
    MCD-DLBCL arises from germinal center B cells.
    Blood. 2022;140:1058-1059.
    >> Share

  217. PHILIPP N, Kazerani M, Nicholls A, Vick B, et al
    T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals.
    Blood. 2022;140:1104-1118.
    >> Share

  218. VOSE JM
    To transplant or not to transplant: that is the question in PTCL.
    Blood. 2022;140:936-937.
    >> Share

  219. BRINK M, Meeuwes FO, van der Poel MWM, Kersten MJ, et al
    Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study.
    Blood. 2022;140:1009-1019.
    >> Share

    August 2022
  220. GASIOROWSKI R, Trotman J
    CAR-T for follicular lymphoma: are we good to go?
    Blood. 2022;140:799-800.
    >> Share

  221. VENKATARAMAN G, Alikhan MB
    Numerous B cells in a mediastinal mass, but not a B-cell lymphoma.
    Blood. 2022;140:932.
    >> Share


  222. Atabay EK, Mecca C, Wang Q, et al. Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma. Blood. 2022;139(5):717-731.
    Blood. 2022;140:794.
    >> Share

  223. OZKAYA N, Jaffe ES
    Splenic diffuse red pulp small B-cell lymphoma with cyclin D3 expression.
    Blood. 2022;140:793.
    >> Share

  224. FLERLAGE JE, Myers JR, Maciaszek JL, Oak N, et al
    Discovery of novel predisposing coding and noncoding variants in familial Hodgkin lymphoma.
    Blood. 2022 Aug 17. pii: 486283. doi: 10.1182/blood.2022016056.
    >> Share

  225. VANDEN BEMPT M, Debackere K, Demeyer S, Van Thillo Q, et al
    Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T cell lymphoma.
    Blood. 2022 Aug 12. pii: 486219. doi: 10.1182/blood.2022016428.
    >> Share

  226. HESLOP HE
    Tumor-intrinsic causes of CAR-T failure.
    Blood. 2022;140:414-415.
    >> Share

  227. SHALABI H, Qin H, Su A, Yates B, et al
    CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.
    Blood. 2022;140:451-463.
    >> Share

  228. FUJISAWA M, Nguyen TB, Abe Y, Suehara Y, et al
    Clonal germinal center B cells function as a niche for T-cell lymphoma.
    Blood. 2022 Aug 3. pii: 486092. doi: 10.1182/blood.2022015451.
    >> Share

  229. CICHOCKI F, Goodridge J, Bjordahl R, Mahmood S, et al
    Dual-antigen targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia.
    Blood. 2022 Aug 2. pii: 486089. doi: 10.1182/blood.2021015184.
    >> Share

  230. KAMBHAMPATI S, Saumoy M, Schneider Y, Serrao S, et al
    Cost Effectiveness of Second-Line Axicabtagene ciloleucel in Relapsed Refractory Diffuse Large B-cell Lymphoma.
    Blood. 2022 Aug 1. pii: 486082. doi: 10.1182/blood.2022016747.
    >> Share

    July 2022
  231. CRAIG A, Wen KW
    EBV-positive high-grade B-cell lymphoma with MYC and BCL6 rearrangements.
    Blood. 2022;140:406.
    >> Share

  232. DARNELL EP, Jacobson CA
    German CARs keeping pace.
    Blood. 2022;140:296-298.
    >> Share

  233. OCAMPO GONZALEZ FA, Ahmed A
    Reed-Sternberg-like cells in a case of follicular lymphoma.
    Blood. 2022;140:290.
    >> Share

  234. ELSAWY M, Chavez JC, Avivi I, Larouche JF, et al
    Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.
    Blood. 2022 Jul 15. pii: 485937. doi: 10.1182/blood.2022015478.
    >> Share

  235. SOUMERAI JD, Rosenthal AC, Harkins SK, Duffy J, et al
    Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma.
    Blood. 2022 Jul 8. pii: 485824. doi: 10.1182/blood.2022015443.
    >> Share

  236. SYRYKH C, Chaouat C, Poullot E, Amara N, et al
    Lymph node excisions provide more precise lymphoma diagnoses than core biopsies: a French Lymphopath network survey.
    Blood. 2022 Jul 7. pii: 485815. doi: 10.1182/blood.2022015520.
    >> Share

  237. ZHOU L, Wang C
    A unique report of breast intravascular NK/T-cell lymphoma mimicking breast carcinoma.
    Blood. 2022;140:78.
    >> Share

  238. BUENO C, Barrera S, Bataller A, Ortiz-Maldonado V, et al
    CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies.
    Blood. 2022;140:38-44.
    >> Share

  239. RUSCONI C, Cheah CY, Eyre TA, Tucker DL, et al
    Ibrutinib improves survival compared to chemotherapy in mantle cell lymphoma with central nervous system relapse.
    Blood. 2022 Jul 5. pii: 485785. doi: 10.1182/blood.2022015560.
    >> Share

    June 2022
  240. QUERFELD C
    Mechanisms of resistance to mogamulizumab.
    Blood. 2022;139:3674-3676.
    >> Share

  241. STRATI P
    CAR T-cell therapy: which product for which patient?
    Blood. 2022;139:3673-3674.
    >> Share

  242. GAUTHIER J, Gazeau N, Hirayama AV, Hill JA, et al
    Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL.
    Blood. 2022;139:3722-3731.
    >> Share

  243. PAREKH A, Keller FG, McCarten KM, Kessel S, et al
    Targeted Radiotherapy for Early-Stage Low-Risk Pediatric Hodgkin Lymphoma Slow Early Responders: A COG AHOD0431 Analysis.
    Blood. 2022 Jun 28. pii: 485708. doi: 10.1182/blood.2022016098.
    >> Share

  244. PINDZOLA GM, Razzaghi R, Tavory RN, Nguyen HT, et al
    Aberrant expansion of spontaneous splenic germinal centers induced by hallmark genetic lesions of aggressive lymphoma.
    Blood. 2022 Jun 27. pii: 485703. doi: 10.1182/blood.2022015926.
    >> Share

  245. FERRERO S, Grimaldi D, Genuardi E, Drandi D, et al
    Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase III trial in mantle cell lymphoma.
    Blood. 2022 Jun 23. pii: 485688. doi: 10.1182/blood.2021014270.
    >> Share

  246. JOHNSON PWM
    Smart salvage treatment for Hodgkin lymphoma.
    Blood. 2022;139:3563-3564.
    >> Share

  247. IZQUIERDO E, Vorholt D, Blakemore S, Sackey B, et al
    Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in TP53-deficient B-cell malignancies.
    Blood. 2022;139:3617-3629.
    >> Share

  248. BACKER K, Wang HY
    Florid reactive follicular hyperplasia with exuberant HHV8 infection.
    Blood. 2022;139:3558.
    >> Share

  249. KAMBHAMPATI S, Saumoy M, Schneider Y, Pak S, et al
    Cost Effectiveness of Polatuzumab Vedotin Combined with Chemoimmunotherapy in Untreated Diffuse Large B-cell Lymphoma.
    Blood. 2022 Jun 14. pii: 485545. doi: 10.1182/blood.2022016624.
    >> Share

  250. GHIONE P, Palomba ML, Patel A, Bobillo S, et al
    Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.
    Blood. 2022 Jun 9. pii: 485518. doi: 10.1182/blood.2021014375.
    >> Share

  251. PETERSON JM, Lyapichev KA
    Extranodal natural killer/T-cell lymphoma of the palate.
    Blood. 2022;139:3450.
    >> Share

  252. FERNANDEZ-SEVILLA LM, Valencia J, Ortiz-Sanchez P, Fraile-Ramos A, et al
    High BMP4 expression in low/intermediate risk BCP-ALL identifies children with poor outcomes.
    Blood. 2022;139:3303-3313.
    >> Share

    May 2022
  253. HAMNVAG HM, Velankar M
    Hemophagocytic lymphohistiocytosis with multiple possible etiologies including rare primary bone marrow lymphoma.
    Blood. 2022;139:3226.
    >> Share

  254. KAMDAR M
    A cauldron of choices.
    Blood. 2022;139:3103-3104.
    >> Share

  255. CERHAN JR
    A (modifiable) way to better Hodgkin lymphoma survivorship?
    Blood. 2022;139:3004-3005.
    >> Share

  256. CALABRETTA E, Hamadani M, Carlo-Stella C
    THE ANTIBODY-DRUG CONJUGATE LONCASTUXIMAB TESIRINE FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA.
    Blood. 2022 May 17. pii: 485279. doi: 10.1182/blood.2021014663.
    >> Share

  257. ALI A, Goy A, Dunleavy K
    CAR T-cell Therapy in Highly-Aggressive B-Cell Lymphoma: Emerging Biological and Clinical Insights.
    Blood. 2022 May 13. pii: 485238. doi: 10.1182/blood.2022016226.
    >> Share

  258. ATANACKOVIC D, Luetkens T, Omili D, Iraguha T, et al
    Vaccine-induced T cells against Sars-Cov-2 and its Omicron variant in B cell-depleted lymphoma patients after CART.
    Blood. 2022 May 10. pii: 485211. doi: 10.1182/blood.2022016175.
    >> Share

  259. CHERNG HJ, Sun R, Sugg B, Irwin R, et al
    Risk assessment with low pass whole genome sequencing of cell free DNA before CD19 CAR T-cells for large B-cell lymphoma.
    Blood. 2022 May 5. pii: 485178. doi: 10.1182/blood.2022015601.
    >> Share

  260. NAKAMURA A, Grossman S, Song K, Xega K, et al
    The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation.
    Blood. 2022;139:2770-2781.
    >> Share

  261. FREY NV
    Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia.
    Blood. 2022 May 4. pii: 485154. doi: 10.1182/blood.2021014892.
    >> Share

    April 2022
  262. TADROS S, Jaffe ES
    A novel case of gamma-delta T-cell lymphoma expressing CD4, recapitulating a stage of gamma-delta T-cell development.
    Blood. 2022;139:2725.
    >> Share


  263. Lowe EJ, Reilly AF, Lim MS, et al. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. Blood. 2021;137(26):3595-3603.
    Blood. 2022;139:2726.
    >> Share

  264. SONIGO G, Bozonnat A, Dumont M, Thonnart N, et al
    Involvement of the CD39/CD73/adenosine pathway in T-cell proliferation and NK cell-mediated antibody-dependent cell cytotoxicity in Sezary syndrome.
    Blood. 2022;139:2712-2716.
    >> Share

  265. JAIN MD, Ziccheddu B, Coughlin CA, Faramand RG, et al
    Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma.
    Blood. 2022 Apr 27. pii: 485092. doi: 10.1182/blood.2021015008.
    >> Share

  266. PORTELL CA
    CNS prophylaxis in DLBCL: first do no harm.
    Blood. 2022;139:2420-2421.
    >> Share

  267. WILSON MR, Eyre TA, Kirkwood AA, Wong Doo N, et al
    Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.
    Blood. 2022;139:2499-2511.
    >> Share

  268. BEYGI S, Duran GE, Fernandez-Pol S, Rook AH, et al
    Resistance to mogamulizumab is associated with loss of CCR4 in Cutaneous T-cell Lymphoma.
    Blood. 2022 Apr 18. pii: 484969. doi: 10.1182/blood.2021014468.
    >> Share

  269. CHONG EA, Schuster SJ
    No CNS sanctuary for lymphoma from CAR T.
    Blood. 2022;139:2261-2263.
    >> Share

  270. BATLEVI CL
    Chemotherapy-free regimens in frontline follicular lymphoma.
    Blood. 2022;139:2263-2264.
    >> Share

  271. QUINTANILLA-MARTINEZ L, Fend F
    Turning up the heat on salivary gland MALT lymphoma.
    Blood. 2022;139:2094-2096.
    >> Share

    March 2022
  272. LIANG HC, Elenitoba-Johnson KSJ
    Targeting IMiD-resistant T-cell lymphoma.
    Blood. 2022;139:1932-1933.
    >> Share

  273. WU W, Nelson GM, Koch R, Donovan KA, et al
    Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1.
    Blood. 2022;139:2024-2037.
    >> Share

  274. QI Y, Zhao M, Hu Y, Wang Y, et al
    Efficacy and safety of CD19-specific CAR T-cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL.
    Blood. 2022 Mar 25. pii: 484499. doi: 10.1182/blood.2021013733.
    >> Share

  275. KURTZ DM
    The many facets of liquid biopsies in lymphoma.
    Blood. 2022;139:1780-1781.
    >> Share

  276. DE MASSON A, Darbord D, Dobos G, Boisson M, et al
    Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients.
    Blood. 2022;139:1820-1832.
    >> Share

  277. SIDDIQI T, Soumerai JD, Dorritie KA, Stephens DM, et al
    Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.
    Blood. 2022;139:1794-1806.
    >> Share

  278. MEI MG, Lee HJ, Palmer J, Chen RW, et al
    Response-adapted anti-PD1 based salvage therapy for Hodgkin lymphoma with nivolumab +/- ICE (NICE).
    Blood. 2022 Mar 22. pii: 484451. doi: 10.1182/blood.2022015423.
    >> Share

  279. BETHGE WA, Martus P, Schmitt M, Holtick U, et al
    GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany.
    Blood. 2022 Mar 22. pii: 484450. doi: 10.1182/blood.2021015209.
    >> Share

  280. SONG Y, Zhou K, Zou DH, Zhou J, et al
    Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study.
    Blood. 2022 Mar 18. pii: 484435. doi: 10.1182/blood.2021014162.
    >> Share

  281. LEONARD JP
    POD24 in follicular lymphoma: time to be "wise".
    Blood. 2022;139:1609-1610.
    >> Share


  282. Bobillo S, Joffe E, Lavery JA, et al. Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era. Blood. 2021;137(1):39-48.
    Blood. 2022;139:1772.
    >> Share

  283. AYPAR U, Ewalt MD
    A very Burkitt-like case of Burkitt-like lymphoma with 11q aberration.
    Blood. 2022;139:1771.
    >> Share

  284. CASULO C, Dixon JG, Le-Rademacher J, Hoster E, et al
    Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials.
    Blood. 2022;139:1684-1693.
    >> Share

  285. PORPACZY E, Jager U
    How I manage autoimmune cytopenias in patients with lymphoid cancer.
    Blood. 2022;139:1479-1488.
    >> Share

  286. NAYAK L, Batchelor TT
    How I treat neurologic complications in patients with lymphoid cancer.
    Blood. 2022;139:1469-1478.
    >> Share

  287. WESTIN JR, Sehn L
    CAR T-cells as a second-line therapy of large B-cell lymphoma: A paradigm shift?
    Blood. 2022 Mar 3. pii: 484263. doi: 10.1182/blood.2022015789.
    >> Share

  288. LULLA PD
    CAR T cells and autologous transplantation can coexist for DLBCL.
    Blood. 2022;139:1266-1267.
    >> Share

  289. SHADMAN M, Pasquini M, Ahn KW, Chen Y, et al
    Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.
    Blood. 2022;139:1330-1339.
    >> Share

    February 2022

  290. Panea RI, Love CL, Shingleton JR, et al. The whole-genome landscape of Burkitt lymphoma subtypes. Blood. 2019;134(19):1598-1607.
    Blood. 2022;139:1256.
    >> Share

  291. MARTIN P, Bartlett NL, Chavez JC, Reagan JL, et al
    Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL.
    Blood. 2022;139:1147-1159.
    >> Share

  292. SHAH NN, Harrington AM
    Hemophagocytosis in cerebrospinal fluid after CAR T-cell therapy.
    Blood. 2022;139:1116.
    >> Share

  293. CHONG EA, Alanio C, Svoboda J, Nasta SD, et al
    Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy.
    Blood. 2022;139:1026-1038.
    >> Share

  294. FRIGAULT MJ, Dietrich J, Gallagher KME, Roschewski MJ, et al
    Safety and Efficacy of Tisagenlecleucel in Primary CNS Lymphoma: A phase I/II clinical trial.
    Blood. 2022 Feb 15. pii: 484042. doi: 10.1182/blood.2021014738.
    >> Share

  295. KIM DH, Vega F
    Relapsed classic Hodgkin lymphoma with decreased CD30 expression after brentuximab and anti-CD30 CAR-T therapies.
    Blood. 2022;139:951.
    >> Share

  296. CAO X, Wang Y, Zhang W, Zhong X, et al
    Targeting macrophages for enhancing CD47 blockade-elicited lymphoma clearance and overcoming tumor-induced suppression.
    Blood. 2022 Feb 8. pii: 483887. doi: 10.1182/blood.2021013901.
    >> Share

  297. DEAGLIO S, Vaisitti T
    A new taxonomy for splenic marginal zone lymphoma.
    Blood. 2022;139:644-645.
    >> Share

  298. YU YT, Chang KC
    Burkitt-like lymphoma with 11q aberrations: a highly apoptotic and high-grade lymphoma.
    Blood. 2022;139:797.
    >> Share

  299. DAVIDS MS, Rogers KA, Tyekucheva S, Wang Z, et al
    Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
    Blood. 2022;139:686-689.
    >> Share

    January 2022
  300. KLEIN U
    Metabolic path toward TCF3 inactivation in Burkitt lymphoma.
    Blood. 2022;139:475-476.
    >> Share

  301. TARIQ H, Zahra U
    Fibrin-associated diffuse large B-cell lymphoma with aberrant CD4 expression.
    Blood. 2022;139:635.
    >> Share

  302. WILKE AC, Doebele C, Zindel A, Lee KS, et al
    SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma.
    Blood. 2022;139:538-553.
    >> Share

  303. AARAKAKI H, Karube K
    Small-cell pattern of DUSP22 rearranged ALK-negative anaplastic large-cell lymphoma with leukemic phase.
    Blood. 2022;139:465.
    >> Share

  304. SCHMITZ N, Frontzek F
    CNS prophylaxis in DLBCL: time to say goodbye?
    Blood. 2022;139:315-317.
    >> Share

  305. ORELLANA-NOIA VM, Reed DR, McCook AA, Sen JM, et al
    Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.
    Blood. 2022;139:413-423.
    >> Share

  306. COTTEREAU AS
    PET imaging: back in the game for gastric EMZL?
    Blood. 2022;139:154-155.
    >> Share

  307. FUJIHARA M, Sakata R, Yoshida N, Ozasa K, et al
    Incidence of lymphoid neoplasms among atomic bomb survivors by histological subtype, 1950 to 1994.
    Blood. 2022;139:217-227.
    >> Share

  308. SHEN Y, Zhou J, Nie K, Cheng S, et al
    Oncogenic role of the SOX9-DHCR24-cholesterol biosynthesis axis in IGH-BCL2+ diffuse large B-cell lymphomas.
    Blood. 2022;139:73-86.
    >> Share

  309. ANDRADES DELGADO A, Alvarez-Perez JC, Patino-Mercau JR, Cuadros M, et al
    Recurrent splice site mutations affect key diffuse large B-cell lymphoma genes.
    Blood. 2022 Jan 5. pii: 483332. doi: 10.1182/blood.2021011708.
    >> Share

    December 2021
  310. MOSKOWITZ AJ, Ghione P, Jacobsen E, Ruan J, et al
    A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.
    Blood. 2021;138:2828-2837.
    >> Share

  311. LIU H, Hu S
    EBV+ ALK+ large B-cell lymphoma.
    Blood. 2021;138:2741.
    >> Share

  312. BACHY E, Houot R, Feugier P, Bouabdallah K, et al
    Obinutuzumab plus lenalidomide (GALEN) in advanced, previously untreated follicular lymphoma in need of systemic therapy.
    Blood. 2021 Dec 22. pii: 483234. doi: 10.1182/blood.2021013526.
    >> Share

  313. HAWKES EA, Barraclough A, Sehn LH
    Limited-stage Diffuse Large B-cell Lymphoma.
    Blood. 2021 Dec 21. pii: 483215. doi: 10.1182/blood.2021013998.
    >> Share

  314. MERIRANTA L, Alkodsi A, Pasanen A, Lepisto M, et al
    Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma.
    Blood. 2021 Dec 21. pii: 483214. doi: 10.1182/blood.2021012852.
    >> Share

  315. JONAK C, Brunner PM
    Blood will tell: profiling Sezary syndrome.
    Blood. 2021;138:2450-2451.
    >> Share

  316. SHOPSOWITZ KE, Slack GW
    B-lymphoblastic lymphoma presenting as a primary breast mass with periductal invasion.
    Blood. 2021;138:2593.
    >> Share

  317. NAJIDH S, Tensen CP, van der Sluijs-Gelling AJ, Teodosio C, et al
    Improved Sezary cell detection and novel insights into immunophenotypic and molecular heterogeneity in Sezary syndrome.
    Blood. 2021;138:2539-2554.
    >> Share

  318. TONC E, Takeuchi Y, Chou C, Xia Y, et al
    Unexpected suppression of tumorigenesis by c-MYC via TFAP4-dependent restriction of stemness in B lymphocytes.
    Blood. 2021;138:2526-2538.
    >> Share

  319. GABALLA MR, Banerjee PP, Milton DR, Jiang X, et al
    Blinatumomab Maintenance After Allogeneic Hematopoietic Cell Transplantation for B-lineage Acute Lymphoblastic Leukemia.
    Blood. 2021 Dec 16. pii: 483090. doi: 10.1182/blood.2021013290.
    >> Share

  320. BUUS TB, Koralov SB
    Oncogenic fusions JAK up CD8+ cytotoxic CTCL.
    Blood. 2021;138:2311-2312.
    >> Share

  321. LEE K, Evans MG, Yang L, Ng S, et al
    Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway.
    Blood. 2021;138:2435-2440.
    >> Share

  322. ALCANTARA M, Houillier C, Blonski M, Rubio MT, et al
    CAR-T cell therapy in primary central nervous system lymphoma (PCNSL): the clinical experience of the French LOC network.
    Blood. 2021 Dec 6. pii: 482903. doi: 10.1182/blood.2021012932.
    >> Share

  323. WILLIAMS AM, Mirzaei Salehabadi S, Xing M, Phillips NS, et al
    Modifiable Risk Factors for Neurocognitive and Psychosocial Problems After Hodgkin Lymphoma.
    Blood. 2021 Dec 3. pii: 482888. doi: 10.1182/blood.2021013167.
    >> Share

  324. WANG Z, Guo R, Trudeau SJ, Wolinsky E, et al
    CYB561A3 is the key lysosomal iron reductase required for Burkitt B-cell growth and survival.
    Blood. 2021;138:2216-2230.
    >> Share

    November 2021
  325. ISHIO T, Kumar S, Shimono J, Daenthanasanmak A, et al
    Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in Adult T-cell leukemia/lymphoma.
    Blood. 2021 Nov 24. pii: 482776. doi: 10.1182/blood.2021012734.
    >> Share

  326. YANG G, Wang J, Tan L, Munshi M, et al
    The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.
    Blood. 2021;138:1966-1979.
    >> Share

  327. WARD J, Berrien-Elliott MM, Gomez F, Luo J, et al
    Phase I/Dose Expansion Trial of Brentuximab vedotin/Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
    Blood. 2021 Nov 15. pii: 477971. doi: 10.1182/blood.2021011894.
    >> Share

  328. FANG H, Xu J
    Peripheral T-cell lymphoma with blastoid morphology and aberrant expression of multiple B-cell antigens.
    Blood. 2021;138:1906.
    >> Share

  329. ZHANG J, Lucas D
    A young microenvironment promotes B-ALL in mice.
    Blood. 2021;138:1789-1790.
    >> Share

  330. OLSEN EA, Whittaker S, Willemze R, Pinter-Brown L, et al
    Primary Cutaneous Lymphoma: Recommendations for Clinical Trial Design and Staging Update from the ISCL, USCLC, and EORTC.
    Blood. 2021 Nov 10. pii: 477944. doi: 10.1182/blood.2021012057.
    >> Share

    October 2021
  331. OKWAN-DUODU D, Huang Q
    Primary splenic Burkitt-like lymphoma with 11q aberration.
    Blood. 2021;138:1642.
    >> Share

  332. KUPPERS R
    Sugar-modified B-cell receptors in DLBCL.
    Blood. 2021;138:1512-1514.
    >> Share

  333. CHIODIN G, Allen JD, Bryant DJ, Rock P, et al
    Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior.
    Blood. 2021;138:1570-1582.
    >> Share

  334. SCHAFF LR, Grommes C
    Primary Central Nervous System Lymphoma.
    Blood. 2021 Oct 26. pii: S0006-4971(21)01788-2. doi: 10.1182/blood.2020008377.
    >> Share

  335. KOGURE Y, Kameda T, Koya J, Yoshimitsu M, et al
    Whole-genome landscape of adult T-cell leukemia/lymphoma.
    Blood. 2021 Oct 25. pii: S0006-4971(21)01784-5. doi: 10.1182/blood.2021013568.
    >> Share

  336. EYRE TA, Cheah CY, Wang ML
    Therapeutic options for relapsed/refractory mantle cell lymphoma.
    Blood. 2021 Oct 22. pii: S0006-4971(21)01781-X. doi: 10.1182/blood.2021013326.
    >> Share

  337. WILSON MH, Gottschalk S
    Expect the unexpected: piggyBac and lymphoma.
    Blood. 2021;138:1379-1380.
    >> Share

  338. GROS A, Merlio JP
    Single-cell trajectories in Sezary syndrome.
    Blood. 2021;138:1384-1386.
    >> Share

  339. LIEBERS N, Speer C, Benning L, Bruch PM, et al
    Humoral and cellular responses after COVID-19 vaccination in anti-CD20 treated lymphoma patients.
    Blood. 2021 Oct 20. pii: 477393. doi: 10.1182/blood.2021013445.
    >> Share

  340. JOHNSTON RL, Mottok A, Chan FC, Jiang A, et al
    Gene expression-based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma.
    Blood. 2021 Oct 18. pii: 477371. doi: 10.1182/blood.2021011941.
    >> Share

  341. KARACA ATABAY E, Mecca C, Wang Q, Ambrogio C, et al
    Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma.
    Blood. 2021 Oct 17. pii: 477348. doi: 10.1182/blood.2020008136.
    >> Share

  342. BONFIGLIO F, Bruscaggin A, Guidetti F, Terzi di Bergamo L, et al
    Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma.
    Blood. 2021 Oct 15. pii: 477330. doi: 10.1182/blood.2021012386.
    >> Share

  343. SANCHEZ-BEATO M
    PD-1 loss and T-cell exhaustion in CTCL tumoral T cells.
    Blood. 2021;138:1201-1203.
    >> Share

  344. PARK J, Daniels J, Wartewig T, Ringbloom KG, et al
    Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity.
    Blood. 2021;138:1225-1236.
    >> Share

    September 2021
  345. XU D, Naresh KN
    Leukemic presentation of a highly aggressive ALK-negative anaplastic large cell lymphoma.
    Blood. 2021;138:1198.
    >> Share

  346. STEPHENS DM, Byrd JC
    Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.
    Blood. 2021;138:1099-1109.
    >> Share

  347. MINDERMAN M, Amir A, Kraan W, Schilder-Tol EJM, et al
    Immune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than 9p24.1/PD-L1/PD-L2 alterations.
    Blood. 2021;138:1194-1197.
    >> Share

  348. LIU F, Gao Y, Xu B, Xiong S, et al
    PEG10 amplification at 7q21.3 potentiates large-cell transformation in cutaneous T-cell lymphoma.
    Blood. 2021 Sep 28. pii: 477066. doi: 10.1182/blood.2021012091.
    >> Share

  349. TENSEN CP, Quint KD, Vermeer MH
    Genetic and epigenetic insights into cutaneous T-cell lymphoma.
    Blood. 2021 Sep 27. pii: 477053. doi: 10.1182/blood.2019004256.
    >> Share

  350. PALLASCH CP
    Cell cycle control in Richter transformation.
    Blood. 2021;138:1005-1007.
    >> Share

  351. GAO J, Sidiropoulou E, Walker I, Krupka JA, et al
    SGK1 mutations in DLBCL generate hyperstable protein neoisoforms that promote AKT independence.
    Blood. 2021;138:959-964.
    >> Share

  352. MAYERHOEFER M, Raderer M, Lamm W, Weber M, et al
    CXCR4 PET/MRI for follow-up of gastric mucosa-associated lymphoid tissue lymphoma after first-line H. pylori eradication.
    Blood. 2021 Sep 15. pii: 476918. doi: 10.1182/blood.2021013239.
    >> Share

  353. OLSZEWSKI A, Kurt H, Evens AM
    Defining and Treating High-grade B-cell lymphoma, NOS.
    Blood. 2021 Sep 15. pii: 476913. doi: 10.1182/blood.2020008374.
    >> Share

  354. DANIELS J, Choi J
    BACH2 is a putative T cell lymphoma tumor suppressor that may play a role in product-derived CAR-T cell lymphomas.
    Blood. 2021 Sep 9. pii: 476840. doi: 10.1182/blood.2021012641.
    >> Share

  355. SAVAGE KJ
    Primary mediastinal Large B-cell Lymphoma.
    Blood. 2021 Sep 9. pii: 476814. doi: 10.1182/blood.2020008376.
    >> Share

  356. GERMANS SK, Chen M
    Myeloid/lymphoid neoplasm with FGFR1 rearrangement.
    Blood. 2021;138:912.
    >> Share

  357. SCHMITT A, Xu W, Bucher P, Grimm M, et al
    Dimethyl fumarate induces ferroptosis and impairs NF-kappaB/STAT3 signaling in DLBCL.
    Blood. 2021;138:871-884.
    >> Share

  358. SCHMIDT RA, Lee AY
    How I treat and prevent venous thrombotic complications in patients with lymphoma.
    Blood. 2021 Sep 3. pii: 476786. doi: 10.1182/blood.2019003689.
    >> Share

  359. CARBONE A, Vaccher E, Gloghini A
    Hematological cancers in individuals infected by HIV.
    Blood. 2021 Sep 1. pii: 476746. doi: 10.1182/blood.2020005469.
    >> Share

    August 2021
  360. YAZDANBAKHSH K
    "Allo" from the (marginal) zone.
    Blood. 2021;138:595-596.
    >> Share

  361. HERLING M, Wahnschaffe L
    Altered epigenetics at the center of NK-LGL leukemia.
    Blood. 2021;138:589-591.
    >> Share

  362. CHOI Y, Diefenbach C
    Expanding landscape for relapsed Hodgkin lymphoma.
    Blood. 2021;138:421-422.
    >> Share

  363. GALINDO-CAMPOS MA, Lutfi N, Bonnin S, Martinez C, et al
    Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice.
    Blood. 2021 Aug 6. pii: 476527. doi: 10.1182/blood.2021012805.
    >> Share

  364. ORICCHIO E
    Epigenetic balance in DLBCL.
    Blood. 2021;138:355-356.
    >> Share

  365. HEWARD J, Konali L, D'Avola A, Close K, et al
    KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas.
    Blood. 2021;138:370-381.
    >> Share

    July 2021
  366. XU W, Berning P, Lenz G
    Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma.
    Blood. 2021 Jul 28. pii: 476467. doi: 10.1182/blood.2020006784.
    >> Share

  367. ADVANI RH, Skrypets T, Civallero M, Spinner MA, et al
    Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project.
    Blood. 2021;138:213-220.
    >> Share

  368. DUNS G, Vigano E, Ennishi D, Sarkozy C, et al
    Characterization of DLBCL with a PMBL gene expression signature.
    Blood. 2021;138:136-148.
    >> Share

  369. TROTMAN J, Pettitt AR
    Is it time for PET-guided therapy in follicular lymphoma.
    Blood. 2021 Jul 14. pii: 476386. doi: 10.1182/blood.2020008243.
    >> Share

  370. HERRERA A, Cheng A, Mimitou EP, Seffens A, et al
    Multimodal single-cell analysis of cutaneous T cell lymphoma reveals distinct sub-clonal tissue-dependent signatures.
    Blood. 2021 Jul 7. pii: 476325. doi: 10.1182/blood.2020009346.
    >> Share

  371. ELUARD B, Nuan-Aliman S, Faumont N, Collares D, et al
    The alternative RelB NF-kappaB subunit is a novel critical player in diffuse large B-cell lymphoma.
    Blood. 2021 Jul 7. pii: 476326. doi: 10.1182/blood.2020010039.
    >> Share

  372. BURKE GAA
    Brentuximab vedotin: frontline help in ALCL.
    Blood. 2021;137:3581-3582.
    >> Share

  373. LOWE EJ, Reilly AF, Lim MS, Gross TG, et al
    Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1.
    Blood. 2021;137:3595-3603.
    >> Share

    June 2021
  374. BALSAS P, Veloza L, Clot G, Sureda-Gomez M, et al
    SOX11, CD70 and Treg cells configure the tumor immune microenvironment of aggressive mantle cell lymphoma.
    Blood. 2021 Jun 29. pii: 476270. doi: 10.1182/blood.2020010527.
    >> Share

  375. GHIONE P, Gu JJ, Attwood K, Torka P, et al
    Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell directed therapies.
    Blood. 2021 Jun 29. pii: 476275. doi: 10.1182/blood.2021012443.
    >> Share

  376. REJESKI K, Perez Perez A, Sesques P, Hoster E, et al
    CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma.
    Blood. 2021 Jun 24. pii: 476241. doi: 10.1182/blood.2020010543.
    >> Share

  377. MULLER MR
    A new option for Richter syndrome.
    Blood. 2021;137:3318-3319.
    >> Share

  378. PEYRON JF
    Blocking RiBi to suppress MYC lymphomagenesis.
    Blood. 2021;137:3316-3318.
    >> Share

  379. WILLIAMS ME
    Mantle cell lymphoma continues to surprise, and inform!
    Blood. 2021;137:3158-3160.
    >> Share

  380. PASTORET C, Desmots F, Drillet G, Le Gallou S, et al
    Linking the KIR phenotype with STAT3 and TET2 mutations to identify chronic lymphoproliferative disorders of NK cells.
    Blood. 2021;137:3237-3250.
    >> Share

  381. KORONA B, Korona D, Zhao W, Wotherspoon A, et al
    GPR34 activation potentially bridges lymphoepithelial lesion to genesis of salivary gland MALT lymphoma.
    Blood. 2021 Jun 4. pii: 476070. doi: 10.1182/blood.2020010495.
    >> Share

  382. CAI J, Qing X
    Splenic marginal zone lymphoma with increased prolymphocytes.
    Blood. 2021;137:3150.
    >> Share

    May 2021
  383. MASS J, Park DC
    Posttransplant T lymphoblastic lymphoma mimicking Burkitt lymphoma.
    Blood. 2021;137:3002.
    >> Share

  384. PLAKS V, Rossi JM, Chou J, Wang L, et al
    CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel.
    Blood. 2021 May 27. pii: 476038. doi: 10.1182/blood.2021010930.
    >> Share

  385. SONG S, Cao C, Choukrallah MA, Tang F, et al
    OBF1 and Oct factors control the germinal center transcriptional program.
    Blood. 2021;137:2920-2934.
    >> Share

  386. BOIKO S, Proia T, San Martin M, Gregory GP, et al
    Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas.
    Blood. 2021;137:2947-2957.
    >> Share

  387. SOUSSAIN C, Malaise D, Cassoux N
    Primary vitreoretinal lymphoma: A diagnostic and management challenge.
    Blood. 2021 May 25. pii: 476013. doi: 10.1182/blood.2020008235.
    >> Share

  388. MAAS-BAUER K, Lohmeyer JK, Hirai T, Lopes Ramos T, et al
    Invariant Natural Killer T Cell Subsets Have Diverse Graft-Versus-Host-Disease-Preventing and Anti-Tumor Effects.
    Blood. 2021 May 25. pii: 476015. doi: 10.1182/blood.2021010887.
    >> Share

  389. REIMANN M, Schrezenmeier J, Richter-Pechanska P, Dolnik A, et al
    Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas.
    Blood. 2021;137:2785-2799.
    >> Share

  390. BISHOP DC, Clancy LE, Simms R, Burgess J, et al
    Development of CAR T-cell lymphoma in two of ten patients effectively treated with piggyBac modified CD19 CAR T-cells.
    Blood. 2021 May 19. pii: 475980. doi: 10.1182/blood.2021010813.
    >> Share

  391. MCMILLAN A
    A new warhead in lymphoma therapy?
    Blood. 2021;137:2568-2570.
    >> Share

  392. VOSE JM
    Outcomes for PTCL: which pathway to success?
    Blood. 2021;137:2570-2571.
    >> Share

  393. SCHMITZ N, Truemper L, Bouabdallah K, Ziepert M, et al
    A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL.
    Blood. 2021;137:2646-2656.
    >> Share

  394. MICKLETHWAITE KP, Gowrishankar K, Gloss BS, Li Z, et al
    Investigation of product derived lymphoma following infusion of piggyBac modified CD19 chimeric antigen receptor T-cells.
    Blood. 2021 May 11. pii: 475942. doi: 10.1182/blood.2021010858.
    >> Share

  395. SILVA AP, Almeida ARM, Cachucho A, Neto JL, et al
    Overexpression of wild type IL-7Ralpha promotes T-cell acute lymphoblastic leukemia/lymphoma.
    Blood. 2021 May 10. pii: 475938. doi: 10.1182/blood.2019000553.
    >> Share

  396. ZHAO Y, Wang E
    An effusion-based presentation of ALK- anaplastic large cell lymphoma.
    Blood. 2021;137:2563.
    >> Share

  397. MAMLOUK O, Nair R, Iyer SP, Edwards A, et al
    Safety of CAR T-cell therapy in kidney transplant recipients.
    Blood. 2021;137:2558-2562.
    >> Share

    April 2021
  398. DAVIES A
    DLBCL outcomes: much ventured, much GAINED.
    Blood. 2021;137:2277-2278.
    >> Share

  399. LE GOUILL S, Ghesquieres H, Oberic L, Morschhauser F, et al
    Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA.
    Blood. 2021;137:2307-2320.
    >> Share

  400. EPPERLA N, Herrera AF
    How we incorporate novel agents into the treatment of classic Hodgkin lymphoma.
    Blood. 2021 Apr 22. pii: 475828. doi: 10.1182/blood.2020007900.
    >> Share

  401. BLOMBERY P, Lade S
    Defining double-hit lymphoma in the clinic.
    Blood. 2021;137:2132-2133.
    >> Share

  402. CHATZIDIMITRIOU C, Vassilakopoulos TP
    Rapidly deteriorating B-CLL at presentation: clonally related Burkitt leukemia as an atypical Richter transformation?
    Blood. 2021;137:2272.
    >> Share

  403. FALCHI L, Ma H, Klein S, Lue JK, et al
    Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.
    Blood. 2021;137:2161-2170.
    >> Share

  404. COLLINGE B, Ben-Neriah S, Chong L, Boyle M, et al
    The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC.
    Blood. 2021;137:2196-2208.
    >> Share

  405. BALA TANNAN N, Manzari MT, Herviou L, Da Silva Ferreira M, et al
    Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition.
    Blood. 2021;137:2057-2069.
    >> Share

  406. SEWASTIANIK T, Straubhaar JR, Zhao JJ, Samur MK, et al
    miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms.
    Blood. 2021;137:1905-1919.
    >> Share

  407. ADVANI R, Moskowitz AJ, Bartlett NL, Vose J, et al
    Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
    Blood. 2021 Apr 7. pii: 475691. doi: 10.1182/blood.2020009178.
    >> Share

  408. CHIHARA D, Dores G, Flowers C, Morton LM, et al
    The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma.
    Blood. 2021 Apr 1. pii: 475679. doi: 10.1182/blood.2020010497.
    >> Share

  409. CAMPO E, Jaffe ES
    Taking gray zone lymphomas out of the shadows.
    Blood. 2021;137:1703-1704.
    >> Share

    March 2021
  410. YU X, Li W, Deng Q, Liu H, et al
    MYD88 L265P elicits mutation-specific ubiquitination to drive NF-kappaB activation and lymphomagenesis.
    Blood. 2021;137:1615-1627.
    >> Share

  411. HAN H, Fan G, Song S, Jiang Y, et al
    piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL.
    Blood. 2021;137:1603-1614.
    >> Share

  412. SHAH NN, Ahn KW, Litovich C, He Y, et al
    Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?
    Blood. 2021;137:1416-1423.
    >> Share

  413. PIGNARRE A, Chatonnet F, Caron G, Haas M, et al
    Plasmablasts derive from CD23- activated B cells after the extinction of IL-4/STAT6 signaling and IRF4 induction.
    Blood. 2021;137:1166-1180.
    >> Share

    February 2021
  414. ILLERHAUS G
    CNS relapse in DLBCL: a calculable risk?
    Blood. 2021;137:1011-1012.
    >> Share

  415. TRUJILLO JA, Godfrey J, Hu Y, Huang J, et al
    Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma.
    Blood. 2021 Feb 24. pii: 475347. doi: 10.1182/blood.2020009148.
    >> Share

  416. DUMONTET E, Pangault C, Roulois D, Desoteux M, et al
    Extracellular vesicles shed by follicular lymphoma B cells promote the polarization of bone marrow stromal cell niche.
    Blood. 2021 Feb 24. pii: 475345. doi: 10.1182/blood.2020008791.
    >> Share

  417. MADDOCKS K
    Building on BTK inhibition in MCL.
    Blood. 2021;137:861-862.
    >> Share

  418. WIRTH A, Mikhaeel NG
    PET response-guided radiotherapy for advanced DLBCL?
    Blood. 2021;137:866-867.
    >> Share

  419. RULAND J
    Synergy of MALT1 and mTOR inhibition in DLBCL.
    Blood. 2021;137:724-725.
    >> Share

  420. VITOLO U, Novo M
    Bcl-2 inhibition in DLBCL: "the times they are a-changing"?
    Blood. 2021;137:577-579.
    >> Share

  421. CASULO C
    Checkpoint blockade in FL: eluding the king.
    Blood. 2021;137:581-582.
    >> Share

  422. RAASTAD K, Huang Q
    Burkitt leukemia with immature B-cell phenotype mimicking acute lymphoblastic leukemia.
    Blood. 2021;137:718.
    >> Share

  423. KOHLHAAS V, Blakemore SJ, Al-Maarri M, Nickel N, et al
    Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1.
    Blood. 2021;137:646-660.
    >> Share

  424. DAHER M, Basar R, Gokdemir E, Baran N, et al
    Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells.
    Blood. 2021;137:624-636.
    >> Share

    January 2021
  425. ABEYKOON JP, Wu X, Nowakowski KE, Dasari S, et al
    Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair.
    Blood. 2021;137:513-523.
    >> Share

  426. GAUTHIER J, Bezerra ED, Hirayama AV, Fiorenza S, et al
    Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
    Blood. 2021;137:323-335.
    >> Share

  427. LOSSOS IS
    Stage I DLBCL: extranodal may mean extra radiation.
    Blood. 2021;137:3-5.
    >> Share

    December 2020
  428. FUKUMOTO K, Sakata-Yanagimoto M, Fujisawa M, Sakamoto T, et al
    VAV1 mutations contribute to development of T-cell neoplasms in mice.
    Blood. 2020;136:3018-3032.
    >> Share

    November 2020
  429. KLINTMAN J, Appleby N, Stamatopoulos B, Ridout K, et al
    Genomic and transcriptomic correlates of Richter's transformation in Chronic Lymphocytic Leukemia.
    Blood. 2020 Nov 18. pii: 474199. doi: 10.1182/blood.2020005650.
    >> Share

  430. VENTURUTTI L, Melnick AM
    The dangers of deja vu: memory B cells as the cells of origin of ABC-DLBCLs.
    Blood. 2020;136:2263-2274.
    >> Share

  431. GANG M, Marin ND, Wong P, Neal CC, et al
    CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas.
    Blood. 2020;136:2308-2318.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016